PL365758A1 - Specific human antibodies for selective cancer therapy - Google Patents
Specific human antibodies for selective cancer therapyInfo
- Publication number
- PL365758A1 PL365758A1 PL01365758A PL36575801A PL365758A1 PL 365758 A1 PL365758 A1 PL 365758A1 PL 01365758 A PL01365758 A PL 01365758A PL 36575801 A PL36575801 A PL 36575801A PL 365758 A1 PL365758 A1 PL 365758A1
- Authority
- PL
- Poland
- Prior art keywords
- human antibodies
- cancer therapy
- specific human
- selective cancer
- selective
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75118100A | 2000-12-29 | 2000-12-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL365758A1 true PL365758A1 (en) | 2005-01-10 |
Family
ID=25020844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL01365758A PL365758A1 (en) | 2000-12-29 | 2001-12-31 | Specific human antibodies for selective cancer therapy |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1353937A4 (fr) |
| JP (1) | JP2004524023A (fr) |
| KR (1) | KR20030091952A (fr) |
| CN (1) | CN100374456C (fr) |
| AU (1) | AU2002246737B2 (fr) |
| BR (1) | BR0116763A (fr) |
| CA (1) | CA2433227A1 (fr) |
| CZ (1) | CZ20031983A3 (fr) |
| HU (1) | HUP0400775A2 (fr) |
| IL (1) | IL156690A0 (fr) |
| MX (1) | MXPA03005944A (fr) |
| NZ (1) | NZ527173A (fr) |
| PL (1) | PL365758A1 (fr) |
| RU (1) | RU2316564C2 (fr) |
| WO (1) | WO2002059264A2 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2491427A1 (fr) * | 2002-07-01 | 2004-01-08 | Savient Pharmaceuticals, Inc. | Compositions et procedes pour traitement therapeutique |
| RU2006102571A (ru) * | 2003-06-30 | 2007-08-20 | Био-Текнолоджи Дженерал(Израиль) Лтд. (IL) | Специфические антитела человека |
| EP2444421A1 (fr) | 2005-04-26 | 2012-04-25 | Pfizer Inc. | Anticorps de la P-Cadherine |
| US8580267B2 (en) | 2008-12-19 | 2013-11-12 | Philogen S.P.A. | Immunocytokines for tumour therapy with chemotherapeutic agents |
| NZ604805A (en) * | 2010-07-09 | 2014-09-26 | Affibody Ab | Polypeptides |
| CN101948534B (zh) * | 2010-08-19 | 2014-05-28 | 中国科学院生物物理研究所 | 一种筛选抗体的方法 |
| GB201310544D0 (en) * | 2013-06-13 | 2013-07-31 | Ucb Pharma Sa | Obtaining an improved therapeutic ligand |
| KR102023289B1 (ko) * | 2014-10-23 | 2019-09-19 | 싱 몰레큘러 메디신, 엘엘씨 | 세포내 항원에 대해 지향된 단일 도메인 항체 |
| US20160176983A1 (en) * | 2014-12-17 | 2016-06-23 | Intrexon Corporation | Intercalated single-chain variable fragments |
| GB201506868D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
| AU2016329542C1 (en) * | 2015-10-01 | 2023-11-23 | Fondazione Centro San Raffaele | TCR and uses thereof |
| WO2017087789A1 (fr) * | 2015-11-19 | 2017-05-26 | Revitope Limited | Complémentation de fragment d'anticorps fonctionnel pour un système à deux composants pour la destruction redirigée de cellules indésirables |
| KR102505681B1 (ko) * | 2016-09-14 | 2023-03-06 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| EP4244251A1 (fr) * | 2020-11-13 | 2023-09-20 | Prometheus Biosciences, Inc. | Méthodes, systèmes et kits pour le traitement d'une maladie inflammatoire ciblant tl1a |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6140470A (en) * | 1995-06-30 | 2000-10-31 | Yale University | Human monoclonal anti-tumor antibodies |
| US6156321A (en) * | 1997-01-22 | 2000-12-05 | Board Of Regents, The University Of Texas System | Tissue factor methods and compositions for coagulation and tumor treatment |
-
2001
- 2001-12-31 PL PL01365758A patent/PL365758A1/xx unknown
- 2001-12-31 BR BR0116763-4A patent/BR0116763A/pt not_active IP Right Cessation
- 2001-12-31 CN CNB018228852A patent/CN100374456C/zh not_active Expired - Fee Related
- 2001-12-31 JP JP2002559551A patent/JP2004524023A/ja active Pending
- 2001-12-31 IL IL15669001A patent/IL156690A0/xx unknown
- 2001-12-31 AU AU2002246737A patent/AU2002246737B2/en not_active Ceased
- 2001-12-31 EP EP01994329A patent/EP1353937A4/fr not_active Withdrawn
- 2001-12-31 CA CA002433227A patent/CA2433227A1/fr not_active Abandoned
- 2001-12-31 RU RU2003123100/13A patent/RU2316564C2/ru not_active IP Right Cessation
- 2001-12-31 HU HU0400775A patent/HUP0400775A2/hu unknown
- 2001-12-31 WO PCT/US2001/049440 patent/WO2002059264A2/fr active IP Right Grant
- 2001-12-31 MX MXPA03005944A patent/MXPA03005944A/es not_active Application Discontinuation
- 2001-12-31 KR KR10-2003-7008885A patent/KR20030091952A/ko not_active Application Discontinuation
- 2001-12-31 CZ CZ20031983A patent/CZ20031983A3/cs unknown
- 2001-12-31 NZ NZ527173A patent/NZ527173A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ527173A (en) | 2006-03-31 |
| MXPA03005944A (es) | 2005-04-29 |
| BR0116763A (pt) | 2004-03-09 |
| CA2433227A1 (fr) | 2002-08-01 |
| JP2004524023A (ja) | 2004-08-12 |
| KR20030091952A (ko) | 2003-12-03 |
| RU2316564C2 (ru) | 2008-02-10 |
| IL156690A0 (en) | 2004-01-04 |
| CZ20031983A3 (cs) | 2005-07-13 |
| EP1353937A4 (fr) | 2005-04-13 |
| EP1353937A2 (fr) | 2003-10-22 |
| AU2002246737B2 (en) | 2007-03-01 |
| CN100374456C (zh) | 2008-03-12 |
| HUP0400775A2 (en) | 2007-05-02 |
| WO2002059264A3 (fr) | 2003-03-06 |
| RU2003123100A (ru) | 2005-03-10 |
| CN1551886A (zh) | 2004-12-01 |
| WO2002059264A2 (fr) | 2002-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1311262A4 (fr) | Traitement combine contre le cancer | |
| GB2386120B (en) | Differentiated cells suitable for human therapy | |
| EP1572131A4 (fr) | Therapie fondee sur les anticorps | |
| GB0028429D0 (en) | Therapy | |
| EP1296699A4 (fr) | Agents therapeutiques - iii | |
| IL214262A0 (en) | Therapeutic human anti-il-1r1 monoclonal antibody | |
| AU2001251348A1 (en) | Apparatus for sensing human prostate tumor | |
| HUP0400775A2 (en) | Specific human antibodies for selective cancer therapy | |
| HUP0300005A3 (en) | Modified cytokines for use in cancer therapy | |
| GB2367993B (en) | Radiotherapy apparatus | |
| EP1178829A4 (fr) | Anticorps monoclonal humain | |
| AU2002351374A8 (en) | Antibodies to treat cancer | |
| GB0001710D0 (en) | Therapeutic treatment | |
| GB0005257D0 (en) | Breast cancer hormonal therapy | |
| EP1401494A4 (fr) | Traitement anti-tumoral | |
| AU144325S (en) | Therapy device | |
| AU2096002A (en) | Therapeutic treatment | |
| GB2374018B (en) | Ultrasound therapy | |
| GB0022216D0 (en) | Human FAP-a-specific antibodies for use in cancer therapy | |
| EP1463511A4 (fr) | Therapie anticancereuse combinatoire | |
| SI1157041T1 (sl) | Protitelesa za terapijo in diagnozo raka | |
| GB0024673D0 (en) | Therapeutic antibodies | |
| GB9914057D0 (en) | Antibody therapy | |
| GB9927698D0 (en) | Therapeutic antibody | |
| GB0015215D0 (en) | Tumour therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DISC | Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications) |